Medifocus (OTCMKTS:MDFZF) vs. INVO Fertility (NASDAQ:IVF) Head-To-Head Review

INVO Fertility (NASDAQ:IVF) and Medifocus (OTCMKTS:MDFZF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 0.7% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for INVO Fertility and Medifocus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	1	2.50
Medifocus	0	0	0	0	0.00

INVO Fertility presently has a consensus price target of $4.00, suggesting a potential upside of 370.64%. Given INVO Fertility’s stronger consensus rating and higher possible upside, research analysts clearly believe INVO Fertility is more favorable than Medifocus.

Valuation and Earnings

This table compares INVO Fertility and Medifocus”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.53 million	0.91	-$9.10 million	($630.29)	0.00
Medifocus	N/A	N/A	N/A	N/A	N/A

Medifocus has lower revenue, but higher earnings than INVO Fertility.

Profitability

This table compares INVO Fertility and Medifocus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-417.02%	N/A	-92.42%
Medifocus	N/A	N/A	N/A

Summary

INVO Fertility beats Medifocus on 6 of the 8 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About Medifocus

Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus, Inc. is based in Toronto, Canada.